For how we live.
In the Scandinavian phase 3 ASAC trial, daily aspirin failed to improve disease-free survival after treatment of colorectal cancer liver metastases — and overall survival was worse on the drug.
In the phase 3 TenCRAOS trial, intravenous tenecteplase given within 4.5 hours did no better than aspirin at recovering sight, and carried more bleeding — including one fatal brain haemorrhage.
For most adults who bruise more than they used to, the cause is thinner skin from ageing, sun or steroids, plus the aspirin and anticoagulants many older people take. A few patterns point elsewhere.
In people with no heart disease, aspirin's benefit was small or absent and bleeding rose across three large trials. US guidance now advises against starting it at 60 or older.
ASPREE randomised 19,114 healthy older adults to low-dose aspirin or placebo. It made no difference to disability-free survival, and modestly raised deaths and major haemorrhage.
PREMIUM tested prasugrel alone against aspirin plus prasugrel in 2,216 STEMI patients in Japan. Monotherapy failed to show noninferiority, and the confidence interval sat above one.
LIBREXIA-ACS enrolled 14,194 patients before stopping for futility. Milvexian did not reduce events, but intracranial and fatal bleeding were identical to placebo, which is the class's whole premise.
Observational studies had linked proton pump inhibitors to fractures, dementia, kidney disease and more. A randomised trial collected all of those outcomes and found only enteric infections.
After 12 months, HbA1c was 6.5% among people managed by community health workers versus 7.1% among those referred to clinics. With 103 participants analysed, the confidence interval crosses zero.
The 162 mg group had 14.1% preterm or severe preeclampsia against 17.1% on 81 mg — a difference the trial could not distinguish from chance. Eight placental abruptions occurred on the higher dose and none on the lower.
A 13-year-old observational hypothesis finally got its randomised test. In ALASCCA, 160 mg of daily aspirin cut three-year recurrence from 14.1% to 7.7% in biomarker-selected patients.